SiBone $SIBN Shares Purchased by HighMark Wealth Management LLC

HighMark Wealth Management LLC lifted its holdings in SiBone (NASDAQ:SIBN) by 549.7% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 159,832 shares of the company’s stock after purchasing an additional 135,232 shares during the period. SiBone makes up 1.3% of HighMark Wealth Management LLC’s holdings, making the stock its 15th biggest holding. HighMark Wealth Management LLC’s holdings in SiBone were worth $3,152,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. State of Alaska Department of Revenue acquired a new position in shares of SiBone in the third quarter valued at approximately $39,000. State of Wyoming acquired a new position in shares of SiBone in the second quarter valued at approximately $55,000. Canada Pension Plan Investment Board acquired a new position in shares of SiBone in the second quarter valued at approximately $68,000. Quarry LP grew its holdings in shares of SiBone by 862.6% in the third quarter. Quarry LP now owns 4,861 shares of the company’s stock valued at $72,000 after purchasing an additional 4,356 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in shares of SiBone by 198.8% in the second quarter. Tower Research Capital LLC TRC now owns 4,897 shares of the company’s stock valued at $92,000 after purchasing an additional 3,258 shares in the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

Analysts Set New Price Targets

SIBN has been the subject of a number of research reports. TD Cowen dropped their price objective on shares of SiBone from $22.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday. Wall Street Zen cut shares of SiBone from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. Finally, Truist Financial reiterated a “buy” rating and issued a $18.00 price target (down from $20.00) on shares of SiBone in a research note on Tuesday. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.00.

SiBone Stock Up 1.9%

Shares of SiBone stock opened at $14.16 on Thursday. SiBone has a 52-week low of $11.48 and a 52-week high of $21.89. The company has a 50 day moving average of $13.34 and a 200 day moving average of $16.12. The company has a quick ratio of 7.21, a current ratio of 9.99 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $628.00 million, a P/E ratio of -36.31 and a beta of 0.67.

SiBone (NASDAQ:SIBN) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.07. SiBone had a negative net margin of 8.10% and a negative return on equity of 9.56%. The company had revenue of $52.59 million during the quarter, compared to the consensus estimate of $51.16 million. As a group, research analysts forecast that SiBone will post -0.52 EPS for the current fiscal year.

Insider Buying and Selling at SiBone

In other news, SVP Michael A. Pisetsky sold 20,756 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $15.35, for a total transaction of $318,604.60. Following the completion of the sale, the senior vice president owned 285,974 shares in the company, valued at approximately $4,389,700.90. The trade was a 6.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Laura Francis sold 93,475 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $15.32, for a total transaction of $1,432,037.00. Following the sale, the chief executive officer owned 544,369 shares of the company’s stock, valued at $8,339,733.08. This represents a 14.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 167,697 shares of company stock worth $2,549,984. 4.00% of the stock is owned by insiders.

SiBone Company Profile

Si-BONE, Inc is a commercial?stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA?cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.